iPSC-derived NK cells engineered with CD226 effectively control acute myeloid leukemia
Runze Cai1, Binyan Lu2, Xiangyu Zhao3
1Department of Cell Biology, School of Basic Medical Sciences, Peking University Stem Cell Research Center, Peking University, Beijing, China.
Experimental Hematology & Oncology
|July 7, 2025
Summary
Engineered induced pluripotent stem cell-derived natural killer (iPSC-NK) cells with CD226 show enhanced killing of acute myeloid leukemia (AML) cells. This immunotherapy approach offers a promising strategy for AML treatment.
Area of Science:
- Immunology
- Cell Biology
- Oncology
Background:
- Natural Killer (NK) cell cytotoxicity is crucial for anti-tumor immunity, but acute myeloid leukemia (AML) cells can evade it by downregulating the CD226 receptor.
- Induced pluripotent stem cell-derived NK (iPSC-NK) cells provide a standardized, off-the-shelf cell therapy source for AML.
- Engineering iPSC-NK cells to overexpress CD226 aims to overcome AML-mediated immune evasion.
Discussion:
- CD226-engineered iPSC-NK cells maintain a typical NK cell phenotype.
- Enhanced anti-AML activity and cytokine release were observed at low effector-to-target ratios.
- Transcriptomic analysis confirmed upregulation of cytotoxicity and immune activation pathways.
Key Insights:
- CD226 overexpression boosts iPSC-NK cell effectiveness against AML.
- iPSC-NK cells engineered with CD226 significantly reduce leukemia burden and prolong survival in an AML xenograft model.
- Reduced systemic inflammation was noted in mice treated with CD226-engineered iPSC-NK cells.
Outlook:
- CD226-engineered iPSC-NK cells represent a promising immunotherapy for AML.
- This approach may also be effective against other malignancies expressing CD226 ligands.
- Further development of off-the-shelf iPSC-NK cell therapies holds significant potential for cancer treatment.
